

# Financial Tear Sheet

## Corporate Profile

Dermira is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering important new treatments to the millions of patients living with chronic skin conditions.

We are committed to understanding the needs of both patients and physicians and using our insight to identify and develop leading-edge medical dermatology clinical programs.

## Stock Information

### DERM (Common Stock)

Exchange NASDAQ GS (US Dollar)

Financial Status Indicator C

Price \$27.06

Change (%) ▲ 0.43 (1.61%)

Volume 417,220

52 Week High \$38.75

52 Week Low \$21.39

Market Cap \$1,127,702,174

Rolling EPS -6.23

PE Ratio 0

Shares Outstanding 41,674,138

Data as of 12/15/17 4:00 p.m. ET



## Recent News

11/09/17

Dermira to Present at Upcoming Investor Conferences in November

11/06/17

Dermira Reports Third Quarter 2017 Financial Results and Announces that FDA Accepts New Drug Application for Glycopyrronium Tosylate for the Treatment of Patients with Primary Axillary Hyperhidrosis

11/06/17

Dermira and UCB Agree to End Collaboration Agreement for CIMZIA

## Upcoming Events

There are currently no events scheduled.

## SEC Filings

Filing Date	Form
12/15/17	4
12/05/17	4
11/06/17	8-K
11/06/17	10-Q

## Corporate Governance

Thomas G. Wiggans	Founder & Chief Executive Officer
Eugene A. Bauer, M.D.	Founder & Chief Medical Officer
Christine Conroy	Senior Vice President, Regulatory Affairs
Janice Drew, MPH	Senior Vice President, Clinical & Project Management
Christopher Griffith	Founder & Vice President, Corporate Development & Strategy
Andrew Guggenhime	Chief Operating Officer & Chief Financial Officer
Hans Hofland, Ph.D.	Vice President, Research
Delphine Imbert, Ph.D.	Senior Vice President, Pharmaceutical Sciences
Luis Peña	Chief Development Officer
Christine Ring, Ph.D.	Vice President, Legal

*Data provided by Nasdaq. Minimum 15 minutes delayed.*